ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00110149

Public ClinicalTrials.gov record NCT00110149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as First Line Treatment in Indolent Non-Hodgkin's Lymphoma

Study identification

NCT ID
NCT00110149
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Enrollment
12 participants

Conditions and interventions

Conditions

Interventions

  • rituximab Biological
  • yttrium Y 90 ibritumomab tiuxetan Radiation

Biological · Radiation

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2004
Primary completion
Apr 30, 2012
Completion
Feb 28, 2015
Last update posted
Nov 20, 2017

2004 – 2015

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center Lebanon New Hampshire 03756-0002
Vermont Cancer Center at University of Vermont Burlington Vermont 05401-3498

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00110149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2017 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00110149 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →